-+ 0.00%
-+ 0.00%
-+ 0.00%

NRx Pharmaceuticals wins FDA clearance to start NRX-101 depression, suicidality trial

PUBT·05/07/2026 12:06:28
Listen to the news
NRx Pharmaceuticals wins FDA clearance to start NRX-101 depression, suicidality trial
  • NRx Pharmaceuticals received FDA clearance to start MIND1, a placebo-controlled Phase 2/3 trial of NRX-101 as adjunct to active or sham robotic-assisted transcranial magnetic stimulation in adults with treatment-resistant major depressive disorder with suicidality.
  • Trial planned to enroll 400 patients, including 240 in randomized portion across a US academic hospital and HOPE Therapeutics clinics, with additional enrollment at two US military treatment facilities.
  • Company targeting non-dilutive funding to support enrollment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605070800PRIMZONEFULLFEED9715195) on May 07, 2026, and is solely responsible for the information contained therein.